CUE on Nasdaq

Cue Biopharma, Inc.

American pharmaceutical preparations company based in Boston.

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with Celularity Inc, Entrada Therapeutics, Inc. or Foghorn Therapeutics Inc., or pick any stock.

  • TickerCUE on Nasdaq
  • IndustryPharmaceutical Preparations
  • HeadquartersCambridge, United States
  • Incorporated inDE2
  • Business address100 Chestnut Street, Suite 300, Somerville, Ma 021432
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-96.7%Operating margin3
-96.9%Net margin3
195.7%Revenue growth, 20253
-100.6%Return on equity3
-$21.9MFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development98¢$37.7M
  • Interest0¢$100.0K
  • Income tax1¢$500.0K

Out of $27.5M in revenue.3 The company lost money this year.

Financial statements

Revenue456783$27.5M in 2025+694% since 2019
0$10.0M$20.0M$30.0M2019: $3.5M$3.5M20192020: $3.2M$3.2M2020−9%2021: $14.9M$14.9M2021+374%2022: $1.2M$1.2M2022−92%2023: $5.5M$5.5M2023+341%2024: $9.3M$9.3M2024+69%2025: $27.5M$27.5M2025+196%
Operating income456783-$26.6M in 2025−28% since 2019
-$60.0M-$40.0M-$20.0M02019: -$36.8M-$36.8M20192020: -$45.0M-$45.0M2020+23%2021: -$43.7M-$43.7M2021−3%2022: -$53.2M-$53.2M2022+22%2023: -$52.1M-$52.1M2023−2%2024: -$41.5M-$41.5M2024−20%2025: -$26.6M-$26.6M2025−36%
Net income456783-$26.6M in 2025−28% since 2019
-$60.0M-$40.0M-$20.0M02019: -$36.7M-$36.7M20192020: -$44.8M-$44.8M2020+22%2021: -$44.2M-$44.2M2021−1%2022: -$53.0M-$53.0M2022+20%2023: -$50.7M-$50.7M2023−4%2024: -$40.7M-$40.7M2024−20%2025: -$26.6M-$26.6M2025−35%

Every line of the income statement as filed: the last 2 fiscal years, latest first.3

Period ending2025-12-312024-12-31
Collaboration revenue$27.5M$9.3M
General and administrative$16.2M$14.6M
Research and development$37.7M$36.3M
Loss (gain) on fixed asset disposal$31.0K-$93.0K
Total operating expenses$54.0M$50.8M
Loss from operations-$26.6M-$41.5M
Interest income$807.0K$1.6M
Interest expense-$357.0K-$796.0K
Total other income, net$450.0K$826.0K
Loss before provision for income taxes-$26.1M-$40.7M
Provision for income taxes-$500.0K$0
Net loss-$26.6M-$40.7M
Net loss per common share - basic-$0.28-$0.72
Net loss per common share - diluted-$0.28-$0.72
Weighted average common shares outstanding, basic94.7M shares56.3M shares
Weighted average common shares outstanding, diluted94.7M shares56.3M shares

Compare Cue Biopharma, Inc. with another company

Leadership

Who has led Cue Biopharma, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Daniel R. Passeri2017–2025
  2. Usman Azam2025–2026
  3. Shao-Lee Lin2026–now

President

  1. Daniel R. Passeri2017–2019
  2. Anish Suri2019–2024

Chief financial officer

  1. Gary Alan Schuman2017
  2. Kerri-Ann Millar2020–2026
  3. James M. Ahlers2026–now
20202025
Board members and other officers (32)

Former names

  • Imagen Biopharma, Inc.Jun 19, 2015 to Jun 19, 20152

Timeline

  1. May 7, 2026New chief executive Shao-Lee Lin becomes CEO11
  2. Oct 2, 2025New chief executive Usman Azam becomes CEO12
  3. Dec 27, 2017New chief executive Daniel R. Passeri becomes CEO13

Filings

296 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 50 major events, 133 insider forms, 19 large holders, 3 private raises, 71 other. The latest 20:

  1. Oct 14, 20264 EDGAR
  2. Oct 14, 20264 EDGAR
  3. Oct 14, 20264 EDGAR
  4. Oct 13, 2026144 EDGAR
  5. Oct 13, 2026144 EDGAR
  6. Oct 8, 2026SCHEDULE 13G/A EDGAR
  7. Sep 21, 20268-K EDGAR
  8. Aug 28, 20264/A EDGAR
  9. Aug 28, 20264/A EDGAR
  10. Aug 21, 2026SCHEDULE 13D EDGAR
  11. Aug 20, 2026EFFECT EDGAR
  12. Aug 18, 2026CORRESP EDGAR
  13. Aug 17, 20264 EDGAR
  14. Aug 17, 20264 EDGAR
  15. Aug 17, 2026UPLOAD EDGAR
  16. Aug 14, 20264 EDGAR
  17. Aug 14, 2026144 EDGAR
  18. Aug 14, 202610-Q EDGAR
  19. Aug 14, 20268-K EDGAR
  20. Aug 14, 2026SCHEDULE 13G EDGAR

The 296 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 19 such filings since October 2021, the latest 10:

  1. Oct 8, 2026SCHEDULE 13G/A
  2. Aug 21, 2026SCHEDULE 13D
  3. Aug 14, 2026SCHEDULE 13G
  4. May 16, 2025SCHEDULE 13G/A
  5. Mar 21, 2025SCHEDULE 13G/A
  6. Feb 14, 2025SCHEDULE 13G/A
  7. Oct 7, 2024SCHEDULE 13G/A
  8. Mar 11, 2024SC 13G
  9. Feb 7, 2024SC 13G
  10. Jan 31, 2024SC 13G

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Jul 13, 2026Raised $50 million in a private offering of equity Form D: 4 investors so far Form D
  2. May 4, 2026Raised $30 million in a private offering of securities Form D: 118 investors so far Form D
  3. Nov 16, 2022Raised $30 million in a private offering of equity Form D: 64 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 49. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Bleichroeder LP370,682$11.7M2.1%New
Driehaus Capital Management LLC292,144$9.2M0.1%New
Vanguard Capital Management LLC161,700$5.1M0.0%New
Ikarian Capital, LLC104,364$3.3M0.5%New
Tetragon Partners GP Ltd93,819$3.0M0.5%New
Stempoint Capital LP66,995$2.1M0.4%New
BlackRock, Inc.57,807$1.8M0.0%New
ADAR1 Capital Management, LLC55,193$1.7M0.1%New
Lion Point Capital, LP52,928$1.7M8.0%New
Squadron Capital Management LLC50,000$1.6M0.5%New
Diadema Partners LP48,369$1.5M0.6%New
Geode Capital Management, LLC47,824$1.5M0.0%New
Boothbay Fund Management, LLC31,459$992.8K0.0%New
UBS Group AG26,700$842.7K0.0%New
Citadel Advisors LLC25,633$809.0K0.0%New
Vanguard Fiduciary Trust Co24,476$772.5K0.0%New
Texas Capital Bank Wealth Management Services Inc22,881$722.1K0.0%New
Renaissance Technologies LLC14,689$463.6K0.0%New
Persistent Asset Partners Ltd12,332$389.2K0.1%New
Robertson Stephens Wealth Management, LLC11,133$351.4K0.0%New
Susquehanna International Group, Llp11,003$347.3K0.0%New
Seven Fleet Capital Management LP10,702$337.8K0.1%New
Northern Trust Corp9,122$287.9K0.0%New
Advisory Research Inc8,573$270.6K0.0%New
Stifel Financial Corp8,218$259.4K0.0%New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46